Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes: a prospective study

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Atopic dermatitis and cancer in solid organs: a systematic review and meta-analysis

    Research output: Contribution to journalComment/debateResearch

  2. Psoriasis and risk of myocardial infarction before and during an era with biological therapy: a population-based follow-up study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The effects of season and weather on healthcare utilization among patients with atopic dermatitis

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Is atopic dermatitis associated with obesity? A systematic review of observational studies

    Research output: Contribution to journalReviewResearchpeer-review

  1. Cause-specific mortality in patients with psoriasis and psoriatic arthritis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Socioeconomic Costs and Health Inequalities from Psoriasis: A Cohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. D-dimer as a potential blood biomarker for disease activity and treatment response in chronic urticaria: a focused review

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

AIM: To examine the effectiveness of omalizumab (anti-IgE) on symptoms and disease-related quality of life in chronic spontaneous urticaria (CSU) and to identify possible patient-specific factors associated with response to omalizumab in patients with antihistamine refractory CSU.

METHODS: Six months prospective trial of omalizumab 300 mg every 4 weeks among patients with CSU from a dermatological university department. The primary outcome was the urticaria activity score in the past week (UAS7) at 3 months.

RESULTS: A total of 117 patients (39 men and 78 women) with a mean age of 42 years were included. The mean baseline UAS7 score was 29.3 points (SD = 10.8), which improved to 11.9 points (SD = 12.9) at 3 months follow-up, difference = 17.4 points (95% CI: 14.8-19.9), P < 0.0001. Other patient-reported outcomes (PROs) also improved significantly during 3 months of treatment. No significant further improvement was seen between three and 6 months follow-up. None of the following patient-specific factors: sex, age, age of onset of CSU, symptom duration, presence of chronic inducible urticaria (CINDU), comorbidities, positive urticaria HR test, smoking, ethnicity, angio-oedema, serum total IgE level, CRP, leucocytes, absolute neutrophil count or previous treatment with prednisolone or montelukast were significantly associated with response to omalizumab at 3 months, P > 0.05 for all comparisons. Previous treatment with traditional immunosuppressant drugs (azathioprine, cyclosporine or methotrexate) was associated with poorer treatment response to omalizumab at 3 months, P < 0.001. A strong correlation was seen between different patient-reported outcomes (PROs) at baseline and 3 months follow-up. Fifteen patients (12.8%) reported side-effects of the treatment.

CONCLUSION: Omalizumab is a highly effective therapy for antihistamine refractory CSU with treatment effects similar to those observed in randomized controlled trials. Validated PROs to assess disease activity, disease control and impairment of quality of life are valuable tools in the clinical management of CSU. Identification of patient-specific predictors of effect and safety of omalizumab in CSU is still warranted.

Original languageEnglish
JournalJournal of the European Academy of Dermatology and Venereology : JEADV
Volume32
Issue number10
Pages (from-to)1761-1767
Number of pages7
ISSN0926-9959
DOIs
Publication statusPublished - Oct 2018

ID: 56259481